Company Description
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases.
Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria.
It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome.
The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020.
Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 380 |
| CEO | Dr. Eric M. Dube Ph.D. |
Contact Details
Address: 3611 Valley Centre Dr, Suite 300 San Diego, California 92130 United States | |
| Phone | 888-969-7879 |
| Website | travere.com |
Stock Details
| Ticker Symbol | TVTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001438533 |
| CUSIP Number | 89422G107 |
| ISIN Number | US89422G1076 |
| Employer ID | 26-2383102 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric M. Dube Ph.D. | President, Chief Executive Officer and Director |
| Christopher Cline C.F.A. | Chief Financial Officer |
| Elizabeth E. Reed J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. William E. Rote Ph.D. | Senior Vice President and Head of Research and Development |
| Peter Heerma | Chief Commercial Officer |
| Sandra Calvin | SVice President, Corporate Controller and Chief Accounting Officer |
| Naomi Eichenbaum | Vice President of Investor Relations |
| Charlotte Smith | Senior Vice President of Public Affairs |
| Angela Giannantonio | Senior Vice President of Human Resources |
| Casey Logan | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 14, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 13, 2024 | 8-K | Current Report |
| May 6, 2024 | 10-Q | Quarterly Report |
| May 6, 2024 | 8-K | Current Report |
| May 1, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 24, 2024 | 8-K | Current Report |
| Mar 27, 2024 | ARS | Filing |
| Mar 27, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 27, 2024 | DEF 14A | Other definitive proxy statements |
| Feb 23, 2024 | 8-K | Current Report |